Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients
暂无分享,去创建一个
C. Maas | P. Gál | H. Farkas | L. Cervenak | J. Dobó | E. Kajdácsi | L. Varga | S. de Maat | N. Veszeli | G. Temesszentandrási | Zsófia Jandrasics | A. Koncz | Veronika Makó | D. Gulyás | Kinga Viktória Köhalmi | Dominik Gulyás
[1] Z. Nemeth,et al. MASP-1 Increases Endothelial Permeability , 2019, Front. Immunol..
[2] H. Farkas,et al. Complete kinetic follow‐up of symptoms and complement parameters during a hereditary angioedema attack , 2018, Allergy.
[3] M. Triggiani,et al. Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes , 2018, International Archives of Allergy and Immunology.
[4] T. Renné,et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. , 2016, The Journal of allergy and clinical immunology.
[5] B. Nilsson,et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation , 2016, Journal of thrombosis and haemostasis : JTH.
[6] Anna E. Engberg,et al. Reciprocal relationship between contact and complement system activation on artificial polymers exposed to whole human blood. , 2016, Biomaterials.
[7] K. Skjødt,et al. The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema , 2015, The Journal of Immunology.
[8] A. Kaplan,et al. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. , 2014, Advances in immunology.
[9] J. Dobó,et al. C1 inhibitor: quantification and purification. , 2014, Methods in molecular biology.
[10] P. Gál,et al. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. , 2013, Molecular immunology.
[11] S. Zeerleder. C1-inhibitor: more than a serine protease inhibitor. , 2011, Seminars in thrombosis and hemostasis.
[12] K. Kekesi,et al. Cleavage of Kininogen and Subsequent Bradykinin Release by the Complement Component: Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 , 2011, PloS one.
[13] H. Farkas,et al. Parameters of the classical complement pathway predict disease severity in hereditary angioedema. , 2011, Clinical immunology.
[14] H. Farkas,et al. Management of upper airway edema caused by hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[15] M. Cicardi,et al. Angioedema due to C1 inhibitor deficiency in 2010 , 2010, Internal and emergency medicine.
[16] Bo Nilsson,et al. Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. , 2009, Biomaterials.
[17] P. Gál,et al. Complement Protease MASP-1 Activates Human Endothelial Cells: PAR4 Activation Is a Link between Complement and Endothelial Function1 , 2009, The Journal of Immunology.
[18] E. Vogler,et al. Contact activation of blood-plasma coagulation. , 2009, Biomaterials.
[19] C. Hack,et al. Structure and function of C1-inhibitor. , 2006, Immunology and allergy clinics of North America.
[20] L. Gráf,et al. Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments 1 , 2003, The Journal of Immunology.
[21] P. Patston,et al. The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[22] C. Hack,et al. In vitro interaction of C1-inhibitor with thrombin , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[23] P. Patston,et al. The inhibition of TNK-t-PA by C1-inhibitor , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[24] M. Kojima,et al. Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors. , 1999, Molecular immunology.
[25] M. Walport,et al. The Complement Factsbook , 1999 .
[26] M. Cicardi,et al. Plasma bradykinin in angio-oedema , 1998, The Lancet.
[27] G. Elgue,et al. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. , 1998, Thrombosis research.
[28] C. Feighery,et al. Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes , 1997, Molecular medicine.
[29] T. Mollnes,et al. Activation of the Complement, Coagulation, Fibrinolytic and Kallikrein–Kinin Systems During Attacks of Hereditary Angioedema , 1996, Immunopharmacology.
[30] T. Mollnes,et al. C3 is Activated in Hereditary Angioedema, and C1/C1‐Inhibitor Complexes Rise During Physical Stress in Untreated Patients , 1995, Scandinavian journal of immunology.
[31] F. Pavalko,et al. Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[32] C. Hack,et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. , 1995, Blood.
[33] A. Eerenberg,et al. Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.
[34] C. Hack,et al. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. , 1993, Blood.
[35] J. Beechem,et al. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. , 1991, Biochemistry.
[36] G. Füst,et al. Concentration of C1 inhibitor in sera of healthy blood donors as studied by immunoenzymatic assay. , 1991, Complement and inflammation.
[37] R. Dwek,et al. Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. , 1990, Journal of molecular biology.
[38] E. Hack,et al. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. , 1990, The Journal of clinical investigation.
[39] R. Colman,et al. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. , 1989, Blood.
[40] V. Schumaker,et al. Expression of hemolytically active human complement component C1r proenzyme in insect cells using a baculovirus vector. , 1989, Complement and inflammation.
[41] C. Hack,et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. , 1988, Blood.
[42] W. V. Van Nostrand,et al. Functional and structural similarities between protease nexin I and C1 inhibitor. , 1988, The Journal of biological chemistry.
[43] A. Kaplan,et al. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. , 1985, Blood.
[44] S. Thorsen,et al. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. , 1984, Biochimica et biophysica acta.
[45] B. Wüthrich,et al. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.
[46] A. Kaplan,et al. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. , 1983, The Journal of biological chemistry.
[47] Robert B Sim,et al. Interaction of 125I‐labelled complement subcomponents C r and C s with protease inhibitors in plasma , 1979, FEBS letters.
[48] N. Cooper,et al. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. , 1975, The Journal of clinical investigation.
[49] K.,et al. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. , 1973, The Journal of clinical investigation.
[50] F. Rosen,et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. , 1971, The Journal of clinical investigation.
[51] R. Colman,et al. Interaction of plasma kallikrein with the C1 inhibitor. , 1970, Journal of immunology.
[52] O. Ratnoff,et al. THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR , 1969, The Journal of experimental medicine.
[53] J. Pensky,et al. Partial purification of a serum inhibitor of C'1-esterase. , 1961, The Journal of biological chemistry.